ASCO: Assessing Low-Dose Chemo in Older, Frail Patients With Gastroesophageal Cancer


Researchers assessed outcomes with different chemo regimen doses in elderly or frail patients with gastroesophageal cancer, in this study presented ahead of the ASCO Annual Meeting.

A phase III study comparing doses of oxaliplatin plus capecitabine in elderly or frail adults with advanced gastroesophageal cancer found that the lowest examined dosage was non-inferior to the highest dosage in terms of delaying progression and minimizing side effects.

The study (abstract 4006) was presented by Peter S. Hall, PhD, of the University of Edinburgh, at a presscast ahead of the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31–June 4 in Chicago.

“Low-dose treatment may be offered to patients who are suitable for chemotherapy but too frail or elderly for a full-dose standard regimen, in the confidence that it can produce superior outcomes without compromising cancer control or survival,” Hall said.

The average age of patients diagnosed with gastroesophageal cancer in the United Kingdom is 75 years, and many are frail, Hall noted. Standard chemotherapy for this condition was developed in trials in which patients were an average of 65 years, and predominantly non-frail. After auditing UK oncologists, Hall and colleagues found that most used reduced chemotherapy schedules to treat their frail or elderly patients with gastroesophageal cancer, but without evidence to guide them.

In a prior phase II study, Hall and colleagues compared three regimens in older patients with advanced gastroesophageal cancer-epirubicin, oxaliplatin, and capecitabine vs oxaliplatin and capecitabine vs capecitabine alone-and found that oxaliplatin plus capecitabine yielded the best results.

This phase III study included 514 patients age 51 to 96 years who were ineligible for full-dose epirubicin, oxaliplatin, and capecitabine because of age or frailty, but who were fit for oxaliplatin plus capecitabine. The patients were randomly assigned 1:1:1 to one of three doses: level A, oxaliplatin 130 mg/m2 once every 21 days plus capecitabine 625 mg/m2 twice a day; level B, 80% of level A dosage; and level C, 60% of level A dosage.

After 9 weeks, patients were scored using a tool called Overall Treatment Utility (OTU), a composite of clinical benefit, tolerability, quality of life, and patient value.

Patients assigned to the lowest dosage, level C, had fewer toxic effects and better OTU outcomes than those assigned to level A or level B. Level C produced the best OTU outcomes, even in younger patients and those who were less frail. No group benefited more from a higher dosage.

Survival outcomes were assessed as secondary measures. Overall and progression-free survival were similar across the three study arms. Median overall survival was 7.5 months for level A, 6.7 months for level B, and 7.6 months for level C. Median progression-free survival was 4.9 months for level A, 4.1 months for level B, and 4.3 months for level C.

Although more than half of patients assigned to level A and level B experienced grade 3 or worse adverse events, this occurred in only 37% of patients assigned to level C.

“One of the things that all oncologists who treat adults struggle with are a lack of data on elderly patients,” said ASCO President Monica M. Bertagnolli, MD, FACS, FASCO. “Sixty percent of the patients we treat are elderly, but unfortunately only 10% of our clinical trials data come from patients who are elderly.”

She praised Hall and colleagues for their dedication to the “very special, but certainly far from uncommon” patient population.

Related Videos
Rates of obesity appear to correlate with increasing incidence of cancer in young populations, according to Monique Gary, DO, MSc, FACS.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD, spoke to the potential of ELI-002 2P as a treatment for minimal residual disease positivity in patients with KRAS-mutant solid tumors.
Related Content